Published in Antimicrob Agents Chemother on February 01, 2005
New complete genome sequences of human rhinoviruses shed light on their phylogeny and genomic features. BMC Genomics (2007) 1.97
Genome-wide diversity and selective pressure in the human rhinovirus. Virol J (2007) 1.94
Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol (2012) 1.24
Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds. J Biol Chem (2009) 1.23
Rhinovirus genome evolution during experimental human infection. PLoS One (2010) 1.21
Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol (2011) 1.16
Crystal structures of enterovirus 71 3C protease complexed with rupintrivir reveal the roles of catalytically important residues. J Virol (2011) 1.12
In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother (2005) 1.07
Cathepsin F cysteine protease of the human liver fluke, Opisthorchis viverrini. PLoS Negl Trop Dis (2009) 1.06
Cleavage of eukaryotic initiation factor eIF5B by enterovirus 3C proteases. Virology (2008) 1.03
In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother (2007) 0.94
Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection. World J Gastroenterol (2010) 0.92
An anti-human ICAM-1 antibody inhibits rhinovirus-induced exacerbations of lung inflammation. PLoS Pathog (2013) 0.91
Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer. Antimicrob Agents Chemother (2008) 0.90
In Vitro Efficacy of Antiviral Compounds against Enterovirus D68. Antimicrob Agents Chemother (2015) 0.86
Rhinovirus 3C protease facilitates specific nucleoporin cleavage and mislocalisation of nuclear proteins in infected host cells. PLoS One (2013) 0.85
Recent developments in antiviral agents against enterovirus 71 infection. J Biomed Sci (2014) 0.85
Role of Marine Natural Products in the Genesis of Antiviral Agents. Chem Rev (2015) 0.82
Structural basis for antiviral inhibition of the main protease, 3C, from human enterovirus 93. J Virol (2011) 0.80
The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir. Antimicrob Agents Chemother (2015) 0.79
Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C. Antimicrob Agents Chemother (2013) 0.78
In Vitro Assessment of Combinations of Enterovirus Inhibitors against Enterovirus 71. Antimicrob Agents Chemother (2016) 0.75
Enterovirus infection in Korean children and anti-enteroviral potential candidate agents. Korean J Pediatr (2012) 0.75
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng (1995) 19.22
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res (1988) 8.53
Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J Mol Biol (1984) 8.06
Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A (1982) 6.09
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
The complete nucleotide sequence of a common cold virus: human rhinovirus 14. Nucleic Acids Res (1984) 3.85
Human rhinovirus 2: complete nucleotide sequence and proteolytic processing signals in the capsid protein region. Nucleic Acids Res (1985) 3.69
Genetic clustering of all 102 human rhinovirus prototype strains: serotype 87 is close to human enterovirus 70. J Gen Virol (2002) 3.30
Viruses and bacteria in the etiology of the common cold. J Clin Microbiol (1998) 3.24
The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae. J Gen Virol (1987) 3.01
Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res (1995) 2.98
Genome of coxsackievirus B3. Virology (1987) 2.88
Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell (1994) 2.84
Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis (2003) 2.81
VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol (2004) 2.56
The nucleotide sequence of coxsackievirus A9; implications for receptor binding and enterovirus classification. J Gen Virol (1989) 2.52
Complete nucleotide sequence of the genome of coxsackievirus B1. Virology (1987) 2.49
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A (1999) 2.44
Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol (1990) 2.19
Molecular analysis of coxsackievirus A16 reveals a new genetic group of enteroviruses. Virology (1994) 2.13
Frequency and natural history of rhinovirus infections in adults during autumn. J Clin Microbiol (1997) 2.09
Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis (2001) 2.02
Human rhinovirus 87 and enterovirus 68 represent a unique serotype with rhinovirus and enterovirus features. J Clin Microbiol (2002) 2.01
Complete nucleotide sequence of a coxsackie B5 virus and its relationship to swine vesicular disease virus. J Gen Virol (1993) 1.76
Complete sequence of the RNA genome of human rhinovirus 16, a clinically useful common cold virus belonging to the ICAM-1 receptor group. Virus Genes (1995) 1.74
The complete nucleotide sequence of coxsackievirus A21. J Gen Virol (1989) 1.70
The nucleotide sequence of human rhinovirus 1B: molecular relationships within the rhinovirus genus. J Gen Virol (1988) 1.67
The complete nucleotide sequence of enterovirus type 70: relationships with other members of the picornaviridae. J Gen Virol (1990) 1.64
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother (1999) 1.63
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem (1999) 1.55
Molecular relationships between 21 human rhinovirus serotypes. J Gen Virol (1995) 1.50
Improved detection of rhinoviruses in clinical samples by using a newly developed nested reverse transcription-PCR assay. J Clin Microbiol (1999) 1.46
Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother (1992) 1.41
Evolutionary relationships within the human rhinovirus genus: comparison of serotypes 89, 2, and 14. Proc Natl Acad Sci U S A (1987) 1.31
Polymerase chain reaction and sequencing for typing rhinovirus RNA. J Med Virol (1994) 1.30
Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother (2003) 1.27
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
Intranasal recombinant alfa-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother (1988) 1.25
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. J Med Chem (1998) 1.24
Molecular cloning and sequence determination of the genomic regions encoding protease and genome-linked protein of three picornaviruses. J Virol (1986) 1.23
Phylogenetic analysis of a coxsackievirus A24 variant: the most recent worldwide pandemic was caused by progenies of a virus prevalent around 1981. Virology (1992) 1.19
In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res (2000) 1.18
Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother (1995) 1.18
Treatment of picornavirus infections. Antiviral Res (2002) 1.15
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem (1998) 1.14
The genome of echovirus 11. Virus Res (1995) 1.14
Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother (2000) 1.13
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J Med Chem (1998) 1.12
The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. J Gen Virol (1986) 1.11
Rhinoviruses: important respiratory pathogens. Ann Med (1998) 1.09
Safety and efficacy evaluation of pleconaril for treatment of the common cold. Clin Infect Dis (2003) 1.06
Molecular cloning and sequence determination of the complete genome of the virulent echovirus 9 strain barty. Virus Genes (1996) 1.06
Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. J Infect Dis (1984) 1.04
Evolutionary analysis of the picornavirus family. J Mol Evol (1995) 1.00
Combined antiviral-antimediator treatment for the common cold. J Infect Dis (2002) 1.00
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem (1999) 0.98
Infectious cDNA clones of echovirus 12 and a variant resistant against the uncoating inhibitor rhodanine differ in seven amino acids. J Virol (1995) 0.96
Construction of a recombinant cDNA of echovirus 6 that established a persistent in vitro infection. Virology (1994) 0.91
Solid-phase synthesis of irreversible human rhinovirus 3C protease inhibitors. Part 1: Optimization of tripeptides incorporating N-terminal amides. Bioorg Med Chem (1999) 0.85
Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antivir Ther (2002) 0.82
Rapid multiserotype detection of human rhinoviruses on optically coated silicon surfaces. J Clin Virol (2001) 0.77
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase. Science (1991) 5.42
Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. I. General features and binding of methotrexate. J Biol Chem (1982) 3.84
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47
Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate. Science (1977) 2.88
The mental health of patients with a chief complaint of chronic fatigue. A prospective evaluation and follow-up. Arch Intern Med (1988) 2.85
Purification and properties of Pseudomonas aeruginosa porin. J Biol Chem (1983) 2.55
Crystal structure of avian dihydrofolate reductase containing phenyltriazine and NADPH. J Biol Chem (1982) 2.45
Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci U S A (1999) 2.44
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Depression and somatization in the chronic fatigue syndrome. Am J Med (1991) 2.33
Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J (2009) 2.14
The frequency of the chronic fatigue syndrome in patients with symptoms of persistent fatigue. Ann Intern Med (1988) 2.11
Mitochondrial outer membrane contains a protein producing nonspecific diffusion channels. J Biol Chem (1980) 2.06
Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem (1997) 2.04
Dihydrofolate reductase from Lactobacillus casei. X-ray structure of the enzyme methotrexate.NADPH complex. J Biol Chem (1978) 1.94
Synaptic plasma membranes from rat brain synaptosomes: isolation and partial characterization. Biochim Biophys Acta (1971) 1.84
X-ray crystallographic study of boronic acid adducts with subtilisin BPN' (Novo). A model for the catalytic transition state. J Biol Chem (1975) 1.82
Identification of variable domains of the attachment (G) protein of subgroup A respiratory syncytial viruses. J Gen Virol (1991) 1.79
Analysis of respiratory syncytial virus strain variation in successive epidemics in one city. J Clin Microbiol (1994) 1.72
Amino acid sequence of the BSC-1 cell growth inhibitor (polyergin) deduced from the nucleotide sequence of the cDNA. Proc Natl Acad Sci U S A (1988) 1.70
What makes the patient-doctor relationship therapeutic? Exploring the connexional dimension of medical care. Ann Intern Med (1988) 1.64
Crystal structure of rat liver dihydropteridine reductase. Proc Natl Acad Sci U S A (1992) 1.63
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother (1999) 1.63
The splicing factor-associated protein, p32, regulates RNA splicing by inhibiting ASF/SF2 RNA binding and phosphorylation. EMBO J (1999) 1.63
Refined crystal structures of Escherichia coli and chicken liver dihydrofolate reductase containing bound trimethoprim. J Biol Chem (1985) 1.62
Crystal structures of Escherichia coli and Lactobacillus casei dihydrofolate reductase refined at 1.7 A resolution. II. Environment of bound NADPH and implications for catalysis. J Biol Chem (1982) 1.61
Alpha-delta sleep in patients with a chief complaint of chronic fatigue. South Med J (1994) 1.55
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem (1999) 1.55
Coexpression of class I major histocompatibility antigen and viral RNA in central nervous system of mice infected with Theiler's virus: a model for multiple sclerosis. Mayo Clin Proc (1992) 1.53
Identification of biased amino acid substitution patterns in human immunodeficiency virus type 1 isolates from patients treated with protease inhibitors. J Virol (1999) 1.50
Mechanism of cytotoxicity of human large granular lymphocytes: relationship of the cytotoxic lymphocyte protein to the ninth component (C9) of human complement. Proc Natl Acad Sci U S A (1986) 1.48
Structure of and kinetic channelling in bifunctional dihydrofolate reductase-thymidylate synthase. Nat Struct Biol (1994) 1.47
The low yield of physical examinations and laboratory investigations of patients with chronic fatigue. Am J Med Sci (1990) 1.47
Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med (1987) 1.44
Juvenile nasopharyngeal angiofibroma: clinical factors associated with recurrence, and proposal of a staging system. J Surg Oncol (2008) 1.44
The role of C3 fragments in endocytosis and extracellular cytotoxic reactions by polymorphonuclear leukocytes. Clin Immunol Immunopathol (1982) 1.42
Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother (2001) 1.37
Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell (1996) 1.37
An electron microscopic study of lesion-induced synaptogenesis in the dentate gyrus of the adult rat. I. Magnitude and time course of degeneration. Brain Res (1976) 1.36
Analysis of relatedness of subgroup A respiratory syncytial viruses isolated worldwide. Virus Res (1992) 1.30
Crystal structure of a novel trimethoprim-resistant dihydrofolate reductase specified in Escherichia coli by R-plasmid R67. Biochemistry (1986) 1.29
Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis (1994) 1.27
Porin from Rhodopseudomonas sphaeroides. J Bacteriol (1984) 1.27
Mechanism of insertion of diphtheria toxin: peptide entry and pore size determinations. Proc Natl Acad Sci U S A (1984) 1.25
Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. J Med Chem (1998) 1.24
Electrostatic channeling in the bifunctional enzyme dihydrofolate reductase-thymidylate synthase. J Mol Biol (1996) 1.23
Design of thymidylate synthase inhibitors using protein crystal structures: the synthesis and biological evaluation of a novel class of 5-substituted quinazolinones. J Med Chem (1993) 1.20
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem (1996) 1.19
Dihydrofolate reductase. The stereochemistry of inhibitor selectivity. J Biol Chem (1985) 1.17
Role of natural killer cells as immune effectors in encephalitis and demyelination induced by Theiler's virus. J Immunol (1989) 1.16
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS (1999) 1.15
Re-examination of the charge relay system in subtilisin comparison with other serine proteases. J Biol Chem (1977) 1.14
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem (1998) 1.14
Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother (2000) 1.13
Induction in vitro of a primary human antiviral cytotoxic T cell response. Eur J Immunol (1995) 1.13
In vivo calcineurin crystals formed using the baculovirus expression system. Microsc Res Tech (1996) 1.13
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J Med Chem (1998) 1.12
A plasmid-encoded dihydrofolate reductase from trimethoprim-resistant bacteria has a novel D2-symmetric active site. Nat Struct Biol (1995) 1.12
Identification of mutations contributing to the reduced virulence of a modified strain of respiratory syncytial virus. Vaccine (1996) 1.11
An electron microscopic study of lesion-induced synaptogenesis in the dentate gyrus of the adult rat. II. Reappearance of morphologically normal synaptic contacts. Brain Res (1976) 1.09
Escherichia coli thymidylate synthase: amino acid substitutions by suppression of amber nonsense mutations. Proc Natl Acad Sci U S A (1990) 1.08
Proteolytic release and crystallization of the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase. J Biol Chem (1991) 1.04
Induced acetylcholinesterase-rich layer in rat dentate gyrus following entorhinal lesions. Brain Res (1972) 1.04
Structural and mechanistic characteristics of dihydropteridine reductase: a member of the Tyr-(Xaa)3-Lys-containing family of reductases and dehydrogenases. Proc Natl Acad Sci U S A (1994) 1.04
Mitochondrial protein p32 can accumulate in the nucleus. Biochem Biophys Res Commun (2001) 1.03
Interaction between herpes simplex virus type 1 IE63 protein and cellular protein p32. J Virol (2000) 1.02
A C9 related channel forming protein in the cytoplasmic granules of human large granular lymphocytes. Biosci Rep (1985) 1.02
Chronic fatigue and chronic fatigue syndrome: clinical epidemiology and aetiological classification. Ciba Found Symp (1993) 1.00
Depression among patients with a chief complaint of chronic fatigue. J Affect Disord (1989) 0.99
Dimeric porin from Paracoccus denitrificans. J Bacteriol (1985) 0.99
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem (1999) 0.98
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother (1995) 0.98
The cytolytic protein of human lymphocytes related to the ninth component (C9) of human complement: isolation from anti-CD3-activated peripheral blood mononuclear cells. Proc Natl Acad Sci U S A (1987) 0.97
Abrogation of resistance to Theiler's virus-induced demyelination in C57BL mice by total body irradiation. J Neuroimmunol (1990) 0.96
Induction of synthesis of the cytolytic C9 (ninth component of complement)-related protein in human peripheral mononuclear cells by monoclonal antibody OKT3 or interleukin 2: correlation with cytotoxicity and lymphocyte phenotype. Proc Natl Acad Sci U S A (1987) 0.95
An immunocytochemical study of choline acetyltransferase-containing neurons and axon terminals in normal and partially deafferented hippocampal formation. Brain Res (1987) 0.95
In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother (2007) 0.94